PLX 2.05 Protalix Biotherapeutics $PLX Hit a 52 week low of 2.05 Closing the day 11/06/14 at 2.05 -0.07 -3.30% With a day low of 2.05 and a total volume of 192,267.
PLX Recent Posts: http://investorshangout.com/Protalix-BioThera...PLX-57243/
PLX Protalix Biotherapeutics Recent Headline News
Stock to Watch: Protalix BioTherapeutics Down 5.3% (PLX)
Comtex SmarTrend(R) - Mon Oct 20, 12:42PM CDT
Protalix BioTherapeutics (AMEX
LX) is one of today's worst performing low-priced stocks, down 5.3% to $2.51 on 1.0x average daily volume. Thus far today, Protalix BioTherapeutics has traded 497,000 shares, vs. average volume of 480,000 shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.1%) and underperformed the S&P 500 (-5.3% to the S&P's 0.6%) during today's trading.
PLX: 2.05 (-0.07)
5 Stocks Ready to Break Out and Soar Higher
at The Street - Mon Oct 20, 9:24AM CDT
These stocks look ready to break out and trade higher from current levels.
VJET: 12.94 (+0.05), RWLK: 29.98 (-0.02), PLX: 2.05 (-0.07), NDLS: 25.75 (+2.94), RGDO: 0.95 (-0.08)
Stock to Watch: Protalix BioTherapeutics Up 5.0% (PLX)
Comtex SmarTrend(R) - Thu Oct 16, 12:41PM CDT
Protalix BioTherapeutics (AMEX LX) is one of today's best performing low-priced stocks, up 5.0% to $2.53 on 1.5x average daily volume. Protalix BioTherapeutics has traded 656,000 shares thus far today, vs. average volume of 453,000 shares per day. The stock has outperformed the Dow (5.0% to the Dow's 0.2%) and outperformed the S&P 500 (5.0% to the S&P's 0.5%) during today's trading.
PLX: 2.05 (-0.07)
Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 22.49 (+0.23), FCSC: 2.67 (-0.09), PLX: 2.05 (-0.07), EPZM: 23.56 (-3.04)
Hot Stock: Protalix BioTherapeutics, Shares Gain 25.0% (PLX)
Comtex SmarTrend(R) - Mon Oct 13, 11:36AM CDT
Protalix BioTherapeutics (AMEX LX) is one of today's best performing low-priced stocks, up 25.0% to $2.75 on 9.8x average daily volume. Thus far today, Protalix BioTherapeutics has traded 3.5 million shares, vs. average volume of 357,000 shares per day. The stock has outperformed the Dow (25.0% to the Dow's -0.3%) and outperformed the S&P 500 (25.0% to the S&P's -0.5%) during today's trading.
PLX: 2.05 (-0.07)
Protalix BioTherapeutics names Moshe Manor as CEO
M2 - Mon Sep 29, 6:38AM CDT
The board of directors of Biopharmaceutical company Protalix BioTherapeutics (NYSE MKT LX) reported on Monday the appointment of Moshe Manor as its new president and chief executive officer from 2 November 2014, succeeding Dr Aviezer.
PLX: 2.05 (-0.07)
Protalix BioTherapeutics Appoints Moshe Manor as President and Chief Executive Officer
GlobeNewswire - Mon Sep 29, 12:59AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT LX) (TASE LX) announced today that its Board of Directors has appointed Mr. Moshe Manor as its new President and Chief Executive Officer. Mr. Manor will assume office on November 2, 2014, when Dr. Aviezer will retire.
PLX: 2.05 (-0.07), TEVA: 58.72 (+0.93)
How Protalix BioTherapeutics (PLX) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 7:42AM CDT
One stock that might be an intriguing choice for investors right now is Protalix BioTherapeutics as this security in the Healthcare industry space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
PLX: 2.05 (-0.07)
Dow 30 Stock Roundup: MSFT Widens Surface Pro 3 Availability, MCD Shutters Several Russia Units - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:12PM CDT
The Dow had a lacklustre week after weakness in energy shares and a series of other concerns dampened investor sentiment.
JNJ: 109.01 (+0.19), GE: 26.36 (+0.54), AMD: 2.76 (-0.04), PFE: 30.04 (unch), PLX: 2.05 (-0.07), MCD: 94.66 (+0.02), MSFT: 48.70 (+0.84), INTC: 33.82 (+0.06), VZ: 50.28 (-0.06)
Protalix BioTherapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 6:46AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT LX) (TASE LX), today announced that Yossi Maimon, the Company's Chief Financial Officer, will present at the Rodman & Renshaw 16 Annual Global Investment Conference on Wednesday, September 10, 2014 at 1:15 PM, Eastern Time. The conference will be held at the New York Palace Hotel in New York City on September 8-10, 2014.
PLX: 2.05 (-0.07)
Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:00PM CDT
Protalix (PLX) and Pfizer (PFE) announced that the FDA has approved Elelyso injection for pediatric patients suffering from type I Gaucher disease.
GILD: 106.94 (+0.89), SHPG: 199.95 (+1.34), PFE: 30.04 (unch), PLX: 2.05 (-0.07)
Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Adds 8.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 8:11AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 8% on the day.
CBPO: 68.98 (+5.71), CBM: 23.48 (+0.55), GILD: 106.94 (+0.89), PLX: 2.05 (-0.07)
Protalix Announces Conference Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional Programs
GlobeNewswire - Thu Aug 28, 4:50PM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT LX) (TASE LX), announced today that it will host a conference call on Wednesday, September 3, 2014 at 8:30am ET to discuss the recent approval of ELELYSO for pediatric patients as jointly announced with Pfizer on August 28, 2014. In addition, the Company's management will also provide an update on the additional ongoing clinical programs, PRX-112 and PRX-102, and hold a Q&A session.
PLX: 2.05 (-0.07)
Why Protalix BioTherapeutics (PLX) Stock Is Surging Today
at The Street - Thu Aug 28, 1:46PM CDT
Protalix BioTherapeutics (PLX) advanced Thursday after the company co-announced with Pfizer (PFE) that the FDA had approved the expansion of ELELYSO for injection in pediatric patients.
PLX: 2.05 (-0.07)
Protalix BioTherapeutics Up 6.6%, Shares Break Through Resistance (PLX)
Comtex SmarTrend(R) - Thu Aug 28, 12:42PM CDT
Protalix BioTherapeutics (AMEX LX) is one of today's best performing low-priced stocks, up 6.6% to $2.57 on 1.9x average daily volume. Protalix BioTherapeutics has traded 715,000 shares thus far today, vs. average volume of 383,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's -0.2%) and outperformed the S&P 500 (6.6% to the S&P's -0.1%) during today's trading.
PLX: 2.05 (-0.07)
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO(TM) (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease
Business Wire - Thu Aug 28, 12:15PM CDT
Pfizer Inc. (NYSE FE) and Protalix BioTherapeutics, Inc. (NYSE-MKT LX, TASE LX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO(TM) (taliglucerase alfa) for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.
PFE: 30.04 (unch), PLX: 2.05 (-0.07)
Hot Stock: Protalix BioTherapeutics, Shares Drop 7.5% (PLX)
Comtex SmarTrend(R) - Wed Aug 20, 10:08AM CDT
Protalix BioTherapeutics (AMEX LX) is one of today's worst performing low-priced stocks, down 7.5% to $2.45 on 1.3x average daily volume. Thus far today, Protalix BioTherapeutics has traded 467,000 shares, vs. average volume of 359,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's 0.2%) and underperformed the S&P 500 (-7.5% to the S&P's 0.1%) during today's trading.
PLX: 2.05 (-0.07)
Investors look to Lighten Up on Shares of Protalix BioTherapeutics, Shares Down 5.9% (PLX)
Comtex SmarTrend(R) - Wed Aug 13, 11:38AM CDT
Protalix BioTherapeutics (AMEX LX) is one of today's worst performing low-priced stocks, down 5.9% to $2.69 on 1.0x average daily volume. Protalix BioTherapeutics has traded 323,000 shares thus far today, vs. average volume of 321,000 shares per day. The stock has underperformed the Dow (-5.9% to the Dow's 0.5%) and underperformed the S&P 500 (-5.9% to the S&P's 0.6%) during today's trading.
PLX: 2.05 (-0.07)
Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT LX) (TASE LX), announced today that it has chosen Mr. Shlomo Yanai as Chairman of the Company's Board of Directors, effective on July 24, 2014. Mr. Zeev Bronfeld, the interim Chairman of the Board, will remain a member of the Board of Directors.
PLX: 2.05 (-0.07)
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
GlobeNewswire - Fri Jun 27, 6:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT LX) (TASE LX), announced today that new clinical data on ELELYSO (taliglucerase alfa) will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel. ELELYSO, the Company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease.
PLX: 2.05 (-0.07)
PLX Recent Posts: http://investorshangout.com/Protalix-BioThera...PLX-57243/
PLX Protalix Biotherapeutics Recent Headline News
Stock to Watch: Protalix BioTherapeutics Down 5.3% (PLX)
Comtex SmarTrend(R) - Mon Oct 20, 12:42PM CDT
Protalix BioTherapeutics (AMEX
LX) is one of today's worst performing low-priced stocks, down 5.3% to $2.51 on 1.0x average daily volume. Thus far today, Protalix BioTherapeutics has traded 497,000 shares, vs. average volume of 480,000 shares per day. The stock has underperformed the Dow (-5.3% to the Dow's -0.1%) and underperformed the S&P 500 (-5.3% to the S&P's 0.6%) during today's trading. PLX: 2.05 (-0.07)
5 Stocks Ready to Break Out and Soar Higher
at The Street - Mon Oct 20, 9:24AM CDT
These stocks look ready to break out and trade higher from current levels.
VJET: 12.94 (+0.05), RWLK: 29.98 (-0.02), PLX: 2.05 (-0.07), NDLS: 25.75 (+2.94), RGDO: 0.95 (-0.08)
Stock to Watch: Protalix BioTherapeutics Up 5.0% (PLX)
Comtex SmarTrend(R) - Thu Oct 16, 12:41PM CDT
Protalix BioTherapeutics (AMEX
LX) is one of today's best performing low-priced stocks, up 5.0% to $2.53 on 1.5x average daily volume. Protalix BioTherapeutics has traded 656,000 shares thus far today, vs. average volume of 453,000 shares per day. The stock has outperformed the Dow (5.0% to the Dow's 0.2%) and outperformed the S&P 500 (5.0% to the S&P's 0.5%) during today's trading. PLX: 2.05 (-0.07)
Protalix BioTherapeutics, Inc. (PLX) in Focus: Stock Surges 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 8:18AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 7% on the day.
EBS: 22.49 (+0.23), FCSC: 2.67 (-0.09), PLX: 2.05 (-0.07), EPZM: 23.56 (-3.04)
Hot Stock: Protalix BioTherapeutics, Shares Gain 25.0% (PLX)
Comtex SmarTrend(R) - Mon Oct 13, 11:36AM CDT
Protalix BioTherapeutics (AMEX
LX) is one of today's best performing low-priced stocks, up 25.0% to $2.75 on 9.8x average daily volume. Thus far today, Protalix BioTherapeutics has traded 3.5 million shares, vs. average volume of 357,000 shares per day. The stock has outperformed the Dow (25.0% to the Dow's -0.3%) and outperformed the S&P 500 (25.0% to the S&P's -0.5%) during today's trading. PLX: 2.05 (-0.07)
Protalix BioTherapeutics names Moshe Manor as CEO
M2 - Mon Sep 29, 6:38AM CDT
The board of directors of Biopharmaceutical company Protalix BioTherapeutics (NYSE MKT
LX) reported on Monday the appointment of Moshe Manor as its new president and chief executive officer from 2 November 2014, succeeding Dr Aviezer. PLX: 2.05 (-0.07)
Protalix BioTherapeutics Appoints Moshe Manor as President and Chief Executive Officer
GlobeNewswire - Mon Sep 29, 12:59AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASE LX) announced today that its Board of Directors has appointed Mr. Moshe Manor as its new President and Chief Executive Officer. Mr. Manor will assume office on November 2, 2014, when Dr. Aviezer will retire. PLX: 2.05 (-0.07), TEVA: 58.72 (+0.93)
How Protalix BioTherapeutics (PLX) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 7:42AM CDT
One stock that might be an intriguing choice for investors right now is Protalix BioTherapeutics as this security in the Healthcare industry space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
PLX: 2.05 (-0.07)
Dow 30 Stock Roundup: MSFT Widens Surface Pro 3 Availability, MCD Shutters Several Russia Units - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 2:12PM CDT
The Dow had a lacklustre week after weakness in energy shares and a series of other concerns dampened investor sentiment.
JNJ: 109.01 (+0.19), GE: 26.36 (+0.54), AMD: 2.76 (-0.04), PFE: 30.04 (unch), PLX: 2.05 (-0.07), MCD: 94.66 (+0.02), MSFT: 48.70 (+0.84), INTC: 33.82 (+0.06), VZ: 50.28 (-0.06)
Protalix BioTherapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 6:46AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASE LX), today announced that Yossi Maimon, the Company's Chief Financial Officer, will present at the Rodman & Renshaw 16 Annual Global Investment Conference on Wednesday, September 10, 2014 at 1:15 PM, Eastern Time. The conference will be held at the New York Palace Hotel in New York City on September 8-10, 2014. PLX: 2.05 (-0.07)
Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 4:00PM CDT
Protalix (PLX) and Pfizer (PFE) announced that the FDA has approved Elelyso injection for pediatric patients suffering from type I Gaucher disease.
GILD: 106.94 (+0.89), SHPG: 199.95 (+1.34), PFE: 30.04 (unch), PLX: 2.05 (-0.07)
Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Adds 8.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 8:11AM CDT
Protalix BioTherapeutics, Inc. (PLX) was a big mover last session, as the company saw its shares rise by over 8% on the day.
CBPO: 68.98 (+5.71), CBM: 23.48 (+0.55), GILD: 106.94 (+0.89), PLX: 2.05 (-0.07)
Protalix Announces Conference Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional Programs
GlobeNewswire - Thu Aug 28, 4:50PM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASE LX), announced today that it will host a conference call on Wednesday, September 3, 2014 at 8:30am ET to discuss the recent approval of ELELYSO for pediatric patients as jointly announced with Pfizer on August 28, 2014. In addition, the Company's management will also provide an update on the additional ongoing clinical programs, PRX-112 and PRX-102, and hold a Q&A session. PLX: 2.05 (-0.07)
Why Protalix BioTherapeutics (PLX) Stock Is Surging Today
at The Street - Thu Aug 28, 1:46PM CDT
Protalix BioTherapeutics (PLX) advanced Thursday after the company co-announced with Pfizer (PFE) that the FDA had approved the expansion of ELELYSO for injection in pediatric patients.
PLX: 2.05 (-0.07)
Protalix BioTherapeutics Up 6.6%, Shares Break Through Resistance (PLX)
Comtex SmarTrend(R) - Thu Aug 28, 12:42PM CDT
Protalix BioTherapeutics (AMEX
LX) is one of today's best performing low-priced stocks, up 6.6% to $2.57 on 1.9x average daily volume. Protalix BioTherapeutics has traded 715,000 shares thus far today, vs. average volume of 383,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's -0.2%) and outperformed the S&P 500 (6.6% to the S&P's -0.1%) during today's trading. PLX: 2.05 (-0.07)
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO(TM) (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease
Business Wire - Thu Aug 28, 12:15PM CDT
Pfizer Inc. (NYSE
FE) and Protalix BioTherapeutics, Inc. (NYSE-MKT LX, TASE LX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO(TM) (taliglucerase alfa) for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. PFE: 30.04 (unch), PLX: 2.05 (-0.07)
Hot Stock: Protalix BioTherapeutics, Shares Drop 7.5% (PLX)
Comtex SmarTrend(R) - Wed Aug 20, 10:08AM CDT
Protalix BioTherapeutics (AMEX
LX) is one of today's worst performing low-priced stocks, down 7.5% to $2.45 on 1.3x average daily volume. Thus far today, Protalix BioTherapeutics has traded 467,000 shares, vs. average volume of 359,000 shares per day. The stock has underperformed the Dow (-7.5% to the Dow's 0.2%) and underperformed the S&P 500 (-7.5% to the S&P's 0.1%) during today's trading. PLX: 2.05 (-0.07)
Investors look to Lighten Up on Shares of Protalix BioTherapeutics, Shares Down 5.9% (PLX)
Comtex SmarTrend(R) - Wed Aug 13, 11:38AM CDT
Protalix BioTherapeutics (AMEX
LX) is one of today's worst performing low-priced stocks, down 5.9% to $2.69 on 1.0x average daily volume. Protalix BioTherapeutics has traded 323,000 shares thus far today, vs. average volume of 321,000 shares per day. The stock has underperformed the Dow (-5.9% to the Dow's 0.5%) and underperformed the S&P 500 (-5.9% to the S&P's 0.6%) during today's trading. PLX: 2.05 (-0.07)
Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASE LX), announced today that it has chosen Mr. Shlomo Yanai as Chairman of the Company's Board of Directors, effective on July 24, 2014. Mr. Zeev Bronfeld, the interim Chairman of the Board, will remain a member of the Board of Directors. PLX: 2.05 (-0.07)
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
GlobeNewswire - Fri Jun 27, 6:00AM CDT
Protalix BioTherapeutics, Inc. (NYSE MKT
LX) (TASE LX), announced today that new clinical data on ELELYSO (taliglucerase alfa) will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel. ELELYSO, the Company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease. PLX: 2.05 (-0.07)
